IL-15 signaling via cis- and trans-presentation to progenitor-exhausted CD8+ T cells enhances radio-immunotherapy efficacy in ESCC
Our findings suggest that IL-15 levels could serve as a biomarker for identifying ESCC patients who are likely to benefit from RT and IM. These results also provide a rationale for targeting IL-15 as a novel therapeutic strategy to enhance treatment outcomes for ESCC patients.
Authors
- Tierun Wang
- Xiaoxue Ma
- Ping Wang (ORCID: https://orcid.org/0000-0001-8992-1233)
- Wencheng Zhang (ORCID: https://orcid.org/0000-0003-3730-5361)
- Shijia Li (ORCID: https://orcid.org/0000-0002-3527-1332)
- Qingsong Pang (ORCID: https://orcid.org/0000-0002-3576-6909)
- Hui Huang (ORCID: https://orcid.org/0009-0004-7836-2703)
- Xi Chen (ORCID: https://orcid.org/0000-0001-9138-1432)
- Tian Zhang (ORCID: https://orcid.org/0000-0001-8914-3531)
- Jiarui Li (ORCID: https://orcid.org/0000-0001-5882-4756)
- Cihui Yan
- Yi You (ORCID: https://orcid.org/0009-0007-2330-1569)
- Jian Zhou (ORCID: https://orcid.org/0000-0001-5859-5404)
- Linrui Gao (ORCID: https://orcid.org/0000-0003-2730-7910)
- Hongyu Bie
- Zisen Nie
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
Publication Details
- Journal
- Journal of Nanobiotechnology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1186/s12951-025-03881-2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00